Talk:Anthracycline
 | This article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | This article was adapted from
Alison Cheong; Sean McGrath; Suzanne Cutts (6 December 2018). "Anthracyclines" (PDF). WikiJournal of Medicine. 5 (1): 1. doi:10.15347/WJM/2018.001. ISSN 2002-4436. Wikidata Q60638523.{{cite journal}}: CS1 maint: unflagged free DOI (link) after peer review (reviewer reports) under a CC BY 4.0 license (2019). |
Idarubicin structure
[edit]There is a mistake - idarubicin has no methoxy group at C-4 position (4-demethoxydaunorubicin). Please correct this mistake, because in these pictures there's no difference between daunorubicin and idarubicin.
- Fixed here. Fvasconcellos (t·c) 18:28, 8 June 2008 (UTC)
Useful references
[edit]For future expansion: doi:10.1124/pr.56.2.6 doi:10.1124/mi.5.3.6 doi:10.1161/01.CIR.0000133187.74800.B9 Fvasconcellos (t·c) 18:28, 8 June 2008 (UTC)
- doi:10.1124/pr.56.2.6 Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
- doi:10.1124/mi.5.3.6 The Cardiotoxicology of Anthracycline Chemotherapeutics: TRANSLATING MOLECULAR MECHANISM INTO PREVENTATIVE MEDICINE
- doi:10.1161/01.CIR.0000133187.74800.B9 Cardiovascular Complications of Cancer Therapy
New ones in clinical trials
[edit]eg: In 2016 GPX-150 was granted Orphan Drug designation by US FDA.[1] - Rod57 (talk) 00:30, 11 February 2016 (UTC)
cardiotoxicity
[edit]I think it's classically described as decreased ejection fraction ultimately leading to dilated cardiomyopathy. — Preceding unsigned comment added by 99.228.106.37 (talk) 18:02, 31 August 2018 (UTC)